Mike Cloonan, Sionna Therapeutics CEO
Sionna selects which cystic fibrosis drug it will study in a mid-stage test
Newly-public biotech Sionna Therapeutics is ready to head into mid-stage testing.
In an update reporting healthy volunteer data for two cystic fibrosis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
